WASP expression and infections
. | WASP . | . | . | |
|---|---|---|---|---|
. | Positive . | Negative . | P . | |
| No. patients for analysis | 21 | 23 | — | |
| Total patient-years observed | 134 | 144 | — | |
| Total episodes of infections | 19 | 96 | — | |
| Total infectious events/patient-year | 0.14 | 0.67 | <.0001 | |
| Bacterial infections, n | 13 | 58 | — | |
| Events/patient-year | 0.10 | 0.40 | .003 | |
| Severe or recurrent viral infections, n | 6 | 24 | — | |
| Events/patient-year | 0.05 | 0.17 | .10∥ | |
| Severe viral infections, n* | 4 | 7 | .93∥ | |
| Recurrent viral infections, n† | 2 | 17 | .01 | |
| Miscellaneous infections, n | 0 | 14§ | — | |
| Events/patient-year | 0 | 0.10 | .001 | |
| Patients with antimicrobial prophylaxis‡ | 1 | 13 | — | |
| Patients without antimicrobial prophylaxis | 26 | 10 | — | |
. | WASP . | . | . | |
|---|---|---|---|---|
. | Positive . | Negative . | P . | |
| No. patients for analysis | 21 | 23 | — | |
| Total patient-years observed | 134 | 144 | — | |
| Total episodes of infections | 19 | 96 | — | |
| Total infectious events/patient-year | 0.14 | 0.67 | <.0001 | |
| Bacterial infections, n | 13 | 58 | — | |
| Events/patient-year | 0.10 | 0.40 | .003 | |
| Severe or recurrent viral infections, n | 6 | 24 | — | |
| Events/patient-year | 0.05 | 0.17 | .10∥ | |
| Severe viral infections, n* | 4 | 7 | .93∥ | |
| Recurrent viral infections, n† | 2 | 17 | .01 | |
| Miscellaneous infections, n | 0 | 14§ | — | |
| Events/patient-year | 0 | 0.10 | .001 | |
| Patients with antimicrobial prophylaxis‡ | 1 | 13 | — | |
| Patients without antimicrobial prophylaxis | 26 | 10 | — | |
WASP-positive numbers represent WASP detectable by Western blot. WASP-negative numbers represent WASP found absent or truncated by Western blot. — indicates not applicable.
WASP-positive patients: CMV hepatitis (n = 3), severe varicella (n = 1). WASP-negative patients: CMV encephalomeningitis (n = 2), measles pneumonitis (n = 2), mumps meningitis (n = 2), EBV reactivation (n = 1).
WASP-positive patients: molluscum contagiosum infections (n = 1), recurrent herpes zoster (n = 1). WASP-negative patients: HSV infections (n = 13), molluscum contagiosum infections (n = 4).
Fungal infections: aspergillosis (n = 3), candidiasis (n = 9), and P carinii pneumonia (n = 2).
WASP-positive patients: trimethoprim-sulfamethoxazole (ST) + amphotericin B (AMPH) (syrup) + acyclovir (ACV, orally) + vancomycin (orally). WASP-negative patients: 12 ST + AMPH (syrup), 1 ST, 2 antibiotics (rifampicin, kanamycin), 1 fluconazole, 1 ACV (orally).
Not significant.